Analysts Expect United Therapeutics Co. (UTHR) Will Announce Quarterly Sales of $349.25 Million
Equities analysts forecast that United Therapeutics Co. (NASDAQ:UTHR) will announce sales of $349.25 million for the current fiscal quarter, according to Zacks. Five analysts have made estimates for United Therapeutics’ earnings. The highest sales estimate is $412.13 million and the lowest is $310.00 million. United Therapeutics reported sales of $444.60 million during the same quarter last year, which suggests a negative year over year growth rate of 21.4%. The company is expected to announce its next earnings results on Thursday, July 26th.
According to Zacks, analysts expect that United Therapeutics will report full year sales of $1.38 billion for the current fiscal year, with estimates ranging from $1.34 billion to $1.42 billion. For the next fiscal year, analysts forecast that the business will report sales of $1.21 billion per share, with estimates ranging from $1.11 billion to $1.38 billion. Zacks’ sales calculations are an average based on a survey of research analysts that cover United Therapeutics.
United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, May 2nd. The biotechnology company reported $5.57 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.62 by $1.95. The company had revenue of $389.20 million during the quarter, compared to the consensus estimate of $393.96 million. United Therapeutics had a return on equity of 26.68% and a net margin of 27.74%. United Therapeutics’s revenue was up 5.0% on a year-over-year basis. During the same period in the previous year, the firm posted $3.61 EPS.
Shares of United Therapeutics opened at $106.58 on Friday, according to MarketBeat Ratings. United Therapeutics has a fifty-two week low of $100.57 and a fifty-two week high of $152.55. The firm has a market capitalization of $4.58 billion, a price-to-earnings ratio of 9.79, a price-to-earnings-growth ratio of 26.91 and a beta of 1.33. The company has a debt-to-equity ratio of 0.11, a current ratio of 5.13 and a quick ratio of 4.81.
In related news, CEO Martine A. Rothblatt sold 43,025 shares of the company’s stock in a transaction on Friday, March 16th. The shares were sold at an average price of $111.11, for a total transaction of $4,780,507.75. Following the completion of the sale, the chief executive officer now directly owns 21,652 shares of the company’s stock, valued at approximately $2,405,753.72. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Martine A. Rothblatt sold 301 shares of the company’s stock in a transaction on Tuesday, March 20th. The stock was sold at an average price of $110.48, for a total transaction of $33,254.48. Following the sale, the chief executive officer now directly owns 21,652 shares of the company’s stock, valued at $2,392,112.96. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 174,046 shares of company stock valued at $19,506,251. 8.20% of the stock is owned by corporate insiders.
A number of institutional investors have recently made changes to their positions in UTHR. Wedge Capital Management L L P NC boosted its position in United Therapeutics by 2,725.8% during the 4th quarter. Wedge Capital Management L L P NC now owns 324,631 shares of the biotechnology company’s stock worth $48,029,000 after purchasing an additional 313,143 shares during the period. Renaissance Technologies LLC boosted its position in United Therapeutics by 14.9% in the 4th quarter. Renaissance Technologies LLC now owns 1,462,378 shares of the biotechnology company’s stock valued at $216,359,000 after buying an additional 189,378 shares during the last quarter. LSV Asset Management boosted its position in United Therapeutics by 53.3% in the 1st quarter. LSV Asset Management now owns 420,340 shares of the biotechnology company’s stock valued at $47,229,000 after buying an additional 146,194 shares during the last quarter. BlackRock Inc. boosted its position in United Therapeutics by 3.0% in the 1st quarter. BlackRock Inc. now owns 4,912,985 shares of the biotechnology company’s stock valued at $552,023,000 after buying an additional 141,416 shares during the last quarter. Finally, Mackay Shields LLC purchased a new position in United Therapeutics in the 1st quarter valued at about $14,199,000. 99.18% of the stock is owned by hedge funds and other institutional investors.
United Therapeutics Company Profile
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.